Finch Therapeutics to Present at the H.C. Wainwright Global Investment Conference

Rhea-AI Summary

Finch Therapeutics Group, a clinical-stage microbiome therapeutics company (Nasdaq: FNCH), announced that CEO Mark Smith, PhD, will present an overview at the H.C. Wainwright Global Investment Conference from May 23-26, 2022. The presentation will be available on-demand starting May 24, 2022, at 7:00 am ET. Finch focuses on developing novel orally administered biological drugs, with its lead candidate, CP101, in late-stage clinical trials for preventing recurrent C. difficile infections. The company also explores treatments for children with autism and partners with Takeda for inflammatory bowel disease therapies.

SOMERVILLE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery^® platform to develop a novel class of orally administered biological drugs, today announced that Mark Smith, PhD, Chief Executive Officer, will present a company overview at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022. The presentation will be available on-demand beginning on Tuesday, May 24, 2022 at 7:00 am ET.

A webcast of the presentation will be available under the ‘Investors & News’ section of the Finch website and will be archived for approximately 30 days.

About Finch Therapeutics

Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery^® platform to develop a novel class of orally administered biological drugs. With the capabilities to develop both complete and targeted microbiome therapeutics, Finch is advancing a rich pipeline of candidates designed to address a wide range of unmet medical needs. Finch’s lead candidate, CP101, is in late-stage clinical development for the prevention of recurrent C. difficile infection and has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration. Finch is also developing FIN-211 for children with autism spectrum disorder and significant gastrointestinal symptoms. Finch has a partnership with Takeda focused on the development of targeted microbiome therapeutics for inflammatory bowel disease. Finch routinely posts information that may be important to its investors on its website at https://www.finchtherapeutics.com/. Finch encourages investors to consult the “Investors & News” section of its website regularly.

Human-First Discovery^® is a registered trademark of Finch Therapeutics Group, Inc.

Investor Contact:

Stephen Jasper
Gilmartin Group
(858) 525-2047
stephen@gilmartinir.com

Media Contact:

Jenna Urban
Berry & Company Public Relations
(212) 253-8881
jurban@berrypr.com

FAQ

When will Finch Therapeutics present at the H.C. Wainwright Global Investment Conference?

Finch Therapeutics will present at the H.C. Wainwright Global Investment Conference from May 23-26, 2022, with the presentation available on-demand starting May 24, 2022, at 7:00 am ET.

What is the lead candidate of Finch Therapeutics?

Finch Therapeutics' lead candidate is CP101, which is in late-stage clinical development for preventing recurrent C. difficile infections.

What designations has CP101 received from the FDA?

CP101 has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration.

What other programs is Finch Therapeutics working on?

Finch Therapeutics is developing FIN-211 for children with autism spectrum disorder and has a partnership with Takeda for developing targeted microbiome therapeutics for inflammatory bowel disease.

How can investors access Finch Therapeutics' presentation?

Investors can access Finch Therapeutics' presentation via the 'Investors & News' section of their website, which will be available for about 30 days after the conference.